Clinical trials: Scoring Systems
- Condition Scoring Systems
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Crohn's Disease
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
The purpose of this study is to evaluate the clinical efficacy of D9421-C 9 mg once daily compared to Mesalazine 1 g three times a day to patients with mild to moderate active Crohn's disease affecting ileum, ileocecal region…
- Trial name
- NCT01514240
- Testing
- D9421-C capsule 3 mg, Mesalazine tablets
- Where
- 25 sites in Japan
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Chronic Spontaneous Urticaria
A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
The purpose of this study was to establish safety and efficacy of ligelizumab in adolescent and adult subjects with Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite standard of care treatment by demonstrating…
- Trial name
- NCT03580369
- Testing
- Ligelizumab, Omalizumab
- Where
- 161 sites in United States, Argentina and 27 more
- Volunteers
- 1,072 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
The purpose of this trial is: 1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by…
- Trial name
- NCT05677451
- Testing
- LOU064 (blinded)
- Where
- 49 sites in United States, Argentina and 15 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
The purpose of this study was to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remained symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab…
- Trial name
- NCT03580356
- Testing
- Ligelizumab, Omalizumab
- Where
- 183 sites in United States, Argentina and 25 more
- Volunteers
- 1,078 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab
The purpose of this extension study was to establish efficacy and safety of ligelizumab. This was assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who had completed a preceding ligelizumab study and…
- Trial name
- NCT04210843
- Testing
- Ligelizumab
- Where
- 273 sites in United States, Argentina and 43 more
- Volunteers
- 1,033 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® Regimen
This is a prospective, open label, single arm, and observational and multicenter study to assess the correlation between PEST and SCORAD scores in the management of AD with the Ceradan® regimen.
- Trial name
- COPES (NCT02073591)
- Testing
- Ceradan Cream, Ceradan Wash
- Where
- 2 sites in Singapore
- Volunteers
- 58 people
- Sponsor
- Hyphens Pharma Pte Ltd
Mobility Impairment, Clinical Workflow Optimization
Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings
This clinical trial evaluates the deployment of humanoid robotics in coalition-aligned healthcare settings. The study measures biometric performance, ESG compliance, and operational impact across patient care, sanitation, and…
- Conditions
- Mobility Impairment, Clinical Workflow Optimization, Sanitation Protocol Compliance, ESG-linked Healthcare Robotics Deployment
- Trial name
- HEALTH (NCT07214896)
- Testing
- Skin Cell Dip, Stem Cell Dip, Wage Token Distribution
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Scorpion Envenomation
AScVS and/ or Prazosin for Scorpion Envenomation
The data available for the efficacy of AScVS and prazosin is generated through different trials done in different clinical setting.
- Trial name
- NCT00753064
- Testing
- Antiscorpion venom serum(AScVS)., T.Prazosin, AScVS + Prazosin
- Where
- 5 sites in India
- Volunteers
- 81 people
- Sponsor
- Haffkine Bio-Pharmaceutical Corporation Ltd.
Allergic Rhinoconjunctivitis, Allergic Asthma
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
The CSMS was defined by the European Academy of Allergy and Immunology Taskforce as a standardised tool to assess clinical effects of allergen-specific immunotherapy (AIT).
- Trial name
- NCT03850626
- Testing
- Immunotherapy
- Where
- Germany
- Volunteers
- 168 people
- Sponsor
- Leti Pharma GmbH
Nasal Obstruction, Common Cold
Observational Study of RHINOSEDAL in Acute Nasal Obstruction
This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study evaluates the performance and safety of RHINOSEDAL in children and adults presenting with acute nasal obstruction…
- Conditions
- Nasal Obstruction, Common Cold, Allergic Rhinitis, Non-allergic Rhinitis
- Trial name
- RHINOSEDAL (NCT07620522)
- Testing
- RHINOSEDAL
- Where
- France
- Volunteers
- 126 people
- Sponsor
- Laboratoires Elerte
Atopic Dermatitis
A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment
In adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile.
- Trial name
- AD-BEASCUITS (NCT06192563)
- Testing
- Dupilumab
- Where
- 9 sites in Italy
- Volunteers
- 230 people
- Sponsor
- Sanofi
Dysphonia
BOTOX® Drug Use Investigation (Spasmodic Dysphonia)
This study is a drug use investigation program of BOTOX. The objective of this investigation is to collect and assess information on the safety and efficacy of BOTOX injections in subjects with a diagnosis of spasmodic dysphonia…
- Trial name
- NCT03543150
- Testing
- BOTOX
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- GlaxoSmithKline